Almac Announces Launch of IXRS®3 Partnership Network
Almac Clinical Technologies, a member of the Almac Group, has announced the launch of its IXRS®3 Partnership Network for biopharmaceutical sponsors, which aims to accelerate the development and delivery of eClinical solutions.
This Partnership Network gives sponsors and CROs the opportunity to share data and solutions to build a more inclusive clinical trial experience for all sites and patients.
Reference
Almac Announces Launch of IXRS®3 Partnership Network. (2023, April 25). Almac.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
